/ /

  • linkedin
  • Increase Font
  • Sharebar

    Regeneron, Avalanche collaborate on gene therapy

    Orlando—Regeneron Pharmaceuticals and Avalanche Biotechnologies announced a collaboration to discover, develop, and commercialize novel gene therapy products for the treatment of ophthalmologic diseases.

    The collaboration covers novel gene therapy vectors and proprietary molecules—discovered jointly by Avalanche and Regeneron—and developed using the Avalanche Ocular BioFactory, an adeno-associated virus-based, proprietary, next-generation platform for the discovery and development of gene therapy vectors for ophthalmology.

    Under the terms of the agreement, Avalanche will receive an upfront cash payment, contingent payments of up to $640 million upon achievement of certain development and regulatory milestones, plus a royalty on worldwide net sales of collaboration products.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results